Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients J. Skrickova, B. Kadlec, O. Venclicek, T. Janaskova, V. Kolek, I. Grygarkova, H. Coupkova, P. Reiterer (Brno, Ostrava, Olomouc, Usti Nad Labem, Czech Republic)
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Session: Systemic therapy of lung cancer and quality of life Session type: Thematic Poster Session Number: 4487
Disease area: Thoracic oncologyRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Skrickova, B. Kadlec, O. Venclicek, T. Janaskova, V. Kolek, I. Grygarkova, H. Coupkova, P. Reiterer (Brno, Ostrava, Olomouc, Usti Nad Labem, Czech Republic). Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients. Eur Respir J 2013; 42: Suppl. 57, 4487
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Survival in 138 patients with non small cell lung cancer (NSCLC) treated with platinum together with gemcitabine or vinorelbine by a multidisciplinary team. Comparison with the Big Lung Trial Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021
Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003